BACKGROUND: Chordomas are very rare low-grade malignant bone tumors that arise from the embryonic rests of the notochord. They are characterized by slow growth and long history with frequent local relapses, and sometimes metastases. While chemotherapy is not efficient, imatinib has shown antitumor activity. CASE PRESENTATION: We report on a 76-year-old patient with EGFR-overexpressing advanced chordoma that progressed on imatinib and subsequently responded to erlotinib during 12 months. CONCLUSIONS: We report the fourth case of advanced chordoma treated with an EGFR inhibitor. We also review the literature concerning the rationale and potential of EGFR targeting in chordoma.
BACKGROUND:Chordomas are very rare low-grade malignant bone tumors that arise from the embryonic rests of the notochord. They are characterized by slow growth and long history with frequent local relapses, and sometimes metastases. While chemotherapy is not efficient, imatinib has shown antitumor activity. CASE PRESENTATION: We report on a 76-year-old patient with EGFR-overexpressing advanced chordoma that progressed on imatinib and subsequently responded to erlotinib during 12 months. CONCLUSIONS: We report the fourth case of advanced chordoma treated with an EGFR inhibitor. We also review the literature concerning the rationale and potential of EGFR targeting in chordoma.
Authors: Elena Tamborini; Francesca Miselli; Tiziana Negri; M Stefania Lagonigro; Samantha Staurengo; Gian Paolo Dagrada; Silvia Stacchiotti; Elisa Pastore; Alessandro Gronchi; Federica Perrone; Antonino Carbone; Marco A Pierotti; Paolo G Casali; Silvana Pilotti Journal: Clin Cancer Res Date: 2006-12-01 Impact factor: 12.531
Authors: Beatriz A Walter; Maria Begnami; Vladimir A Valera; Mariarita Santi; Elisabeth J Rushing; Martha Quezado Journal: J Neurooncol Date: 2010-07-10 Impact factor: 4.130
Authors: Paul M Weinberger; Ziwei Yu; Diane Kowalski; John Joe; Phillip Manger; Amanda Psyrri; Clarence T Sasaki Journal: Arch Otolaryngol Head Neck Surg Date: 2005-08
Authors: Konrad Ptaszyński; Anna Szumera-Ciećkiewicz; Joanna Owczarek; Anna Mrozkowiak; Monika Pekul; Joanna Barańska; Piotr Rutkowski Journal: Pol J Pathol Date: 2009 Impact factor: 1.072
Authors: S Stacchiotti; A Marrari; E Tamborini; E Palassini; E Virdis; A Messina; F Crippa; C Morosi; A Gronchi; S Pilotti; P G Casali Journal: Ann Oncol Date: 2009-07-01 Impact factor: 32.976
Authors: Elena Tamborini; Emanuela Virdis; Tiziana Negri; Marta Orsenigo; Silvia Brich; Elena Conca; Alessandro Gronchi; Silvia Stacchiotti; Giacomo Manenti; Paolo G Casali; Marco A Pierotti; Silvana Pilotti Journal: Neuro Oncol Date: 2010-02-17 Impact factor: 12.300
Authors: Jason M Davies; Aaron E Robinson; Cynthia Cowdrey; Praveen V Mummaneni; Gregory S Ducker; Kevan M Shokat; Andrew Bollen; Byron Hann; Joanna J Phillips Journal: J Neurosurg Date: 2013-11-29 Impact factor: 5.115
Authors: Andrew C Nelson; Nischalan Pillay; Stephen Henderson; Nadège Presneau; Roberto Tirabosco; Dina Halai; Fitim Berisha; Paul Flicek; Derek L Stemple; Claudio D Stern; Fiona C Wardle; Adrienne M Flanagan Journal: J Pathol Date: 2012-09-26 Impact factor: 7.996
Authors: Salvatore Di Maio; Stephen Yip; Gmaan A Al Zhrani; Fahad E Alotaibi; Abdulrahman Al Turki; Esther Kong; Robert C Rostomily Journal: Ther Clin Risk Manag Date: 2015-05-26 Impact factor: 2.423
Authors: Stefanie Scheil-Bertram; Roland Kappler; Alexandra von Baer; Erich Hartwig; Michael Sarkar; Massimo Serra; Silke Brüderlein; Bettina Westhoff; Ingo Melzner; Birgit Bassaly; Jochen Herms; Heinz-Hermann Hugo; Michael Schulte; Peter Möller Journal: Int J Oncol Date: 2014-01-21 Impact factor: 5.650
Authors: Tianna Zhao; I-Mei Siu; Tara Williamson; Haoyu Zhang; Chenchen Ji; Peter C Burger; Nick Connis; Jacob Ruzevick; Menghang Xia; Lucia Cottone; Adrienne M Flanagan; Christine L Hann; Gary L Gallia Journal: J Pathol Date: 2021-07-28 Impact factor: 9.883
Authors: I-Mei Siu; Jacob Ruzevick; Qi Zhao; Nick Connis; Yuchen Jiao; Chetan Bettegowda; Xuewei Xia; Peter C Burger; Christine L Hann; Gary L Gallia Journal: PLoS One Date: 2013-11-15 Impact factor: 3.240